AbbVie completes acquisition of Gilgamesh Pharmaceuticals' bretisilocin [Yahoo! Finance]
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: Yahoo! Finance
Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder. This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See Insiders' Hot Stocks on TipRanks Read More on ABBV: Disclaimer & Disclosure Report an Issue AbbVie price target raised to $250 from $236 at Raymond James 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025 AbbVie's Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact AbbVie's Venetoclax Stud
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research (NASDAQ:GHRS) had its price target lowered by analysts at HC Wainwright from $40.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- GH Research (NASDAQ:GHRS) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GHRS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen<MarketBeat
- GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- GH Research Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
GHRS
Earnings
- 5/8/25 - Beat
GHRS
Sec Filings
- 11/24/25 - Form 6-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- GHRS's page on the SEC website